Bend the cost and time curve for drug discovery and development
OneRNA® delivers quantitative CLIA -validated whole-transcriptome RNA from archival FFPE, CTCs, and liquid biopsy (blood, saliva, urine)
Target Validation
Accelerate target validation in real patient samples. Validate and prioritize targets directly in archival FFPE and liquid biopsy from real patients — not cell lines — on a clinical timeline.
Design Studies
Design clinical studies and identify companion drugs. One whole-transcriptome assay directs arm assignment, enables novel combinations, and enables design.
De-risk
De-risk and accelerate clinical studies with OneRNA® CDx AI. Derive the CDx from whole-transcriptome RNA on an AI endpoint — the deliverable is an algorithm, not a single biomarker: under $1M and structurally de-risked.
Expand
Expand FDA labels to new responder populations. One oncogenic driver spans many tumor types — surface the responder populations that extend an approved drug’s label.
Access
Access longitudinal clinical data and samples. Whole-transcriptome RNA linked to clinical outcomes over time — a longitudinal, multimodal resource of data and samples.
Rescue
Rescue failed drugs by recovering hidden efficacy signals. Recover efficacy signals hidden in unselected trials — re-identify the patients a shelved drug actually helps.
